endovascular.es

Título: ArtVentive Medical Begins Testing the Next Generation of its EOS™ Technology
Fecha: 04-12-2015
CARLSBAD, Calif.--(BUSINESS WIRE)--ArtVentive Medical Group, Inc. (OTC Bulletin Board AVTD) announced today that the Company conducted its first animal study of its next generation of the ArtVentive Endoluminal Occlusion System (EOS™ Gen II). The EOS™ is designed for use in the peripheral vasculature and offers immediate and permanent vessel occlusion in arterial and venous settings.
“The first EOS™ Gen II animal study produced excellent clinical results, demonstrating the safety and effectiveness of this advanced embolization therapy.”
Tweet this
“This new generation of the ArtVentive EOS™ peripheral device represents a significant step forward in the EOS™ technology and design, offering profile reductions, reversibility, enhanced control over deployment and the opportunity to advance into new indications. These advancements allow for the development of devices of varying diameters – with the ability to treat smaller and larger vessel sizes – necessary to meet growing market demands,” stated Leon Rudakov, PhD, President and CTO of ArtVentive. “The first EOS™ Gen II animal study produced excellent clinical results, demonstrating the safety and effectiveness of this advanced embolization therapy.”
About ArtVentive Medical Group, Inc.
ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS™.
The ArtVentive EOS™ is a catheter-based, self-expandable device, which facilitates permanent and immediate occlusion of peripheral vessels. The ArtVentive EOS™ is designed to serve as a safe and reliable alternative to major surgery in certain cases.
More information about ArtVentive can be found at www.artventivemedical.com.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company’s current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company’s control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company’s ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.

Contacts
ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, 760-471-7700
Chief Executive Officer
hjgraham@artventivemedical.com
Fuente: endovascular.es

endovasculares.es